Figure 2.
Cumulative incidence of relapse, PFS, and OS in patients with DLBCL and HGBCL receiving prophylactic HDMTX.

Cumulative incidence of relapse, PFS, and OS in patients with DLBCL and HGBCL receiving prophylactic HDMTX.

Close Modal

or Create an Account

Close Modal
Close Modal